Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,382 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Virus Infection Clear all
Completed Phase 1 Interventional

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

NCT02008578
View directory record Official record
Conditions
Influenza
Interventions
Intravenous hyperimmune immunoglobulin (Flu-IVIG), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Pomegranate Products for Prevention of Common Cold

NCT00617318
View directory record Official record
Conditions
Influenza, Common Cold, Cough, Headache, Fever
Interventions
Pomegranate, Placebo
Dietary Supplement
Lead sponsor
Texas Heart Institute
Other
Eligibility
21 Years to 49 Years
Enrollment
461 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Not applicable Interventional

A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

NCT00001123
View directory record Official record
Conditions
Hantavirus Pulmonary Syndrome
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 2, 2026, 3:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

NCT05572658
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
10,994 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
109
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 2, 2026, 3:34 AM EDT
Completed No phase listed Observational

Risks of COVID19 in the Pregnant Population

NCT04379284
View directory record Official record
Conditions
COVID19
Interventions
Biospecimen collection
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Not applicable Interventional Results available

Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention

NCT05453201
View directory record Official record
Conditions
Long COVID
Interventions
Long COVID Coping and Recovery (LCCR) Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Novartis H1N1 Vaccine in Pregnant Women

NCT00992719
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
6
States / cities
Baltimore, Maryland • St Louis, Missouri • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

NCT05127434
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
36,814 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
133
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 3:34 AM EDT
Active, not recruiting Phase 4 Interventional

Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients

NCT05060991
View directory record Official record
Conditions
COVID-19, Immunosuppression, Vaccine Response Impaired
Interventions
Reduction in antimetabolite immunosuppression
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 2, 2026, 3:34 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474
View directory record Official record
Conditions
COVID-19 Infection
Interventions
ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
69
States / cities
Canoga Park, California • Granada Hills, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Not applicable Interventional

A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases

NCT05035420
View directory record Official record
Conditions
COVID-19, Upper Respiratory Infection, Lower Respiratory Infection
Interventions
Fitbit, Douglas Bag, Periflux 6000 EPOS, BIOPAC, Flowmet, NIRS
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 78 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 2, 2026, 3:34 AM EDT
Completed No phase listed Observational

Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients

NCT04854980
View directory record Official record
Conditions
Covid19, Cancer
Interventions
Blood Sample
Other
Lead sponsor
University of Rochester
Other
Eligibility
50 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 2, 2026, 3:34 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs

NCT04924803
View directory record Official record
Conditions
Covid19
Interventions
No video, Video Text
Behavioral
Lead sponsor
NDRI-USA, Inc.
Other
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 2, 2026, 3:34 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

How Healthy Adults Respond to the Nasal Flu Vaccine

NCT07726862
View directory record Official record
Conditions
Mucosal Immune Response to Influenza Vaccination
Interventions
FluMist (Live Attenuated Influenza Vaccine)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 2, 2026, 3:34 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Conversations You Want About Corona Virus Disease (COVID-19)

NCT05191420
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

NCT04368988
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 84 Years
Enrollment
1,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 2, 2026, 3:34 AM EDT
Terminated Not applicable Interventional

Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device

NCT04595903
View directory record Official record
Conditions
COVID-19
Interventions
Hemopurifier
Device
Lead sponsor
Aethlon Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
9
States / cities
Irvine, California • Loma Linda, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults

NCT07019883
View directory record Official record
Conditions
Avian Influenza
Interventions
H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Durham, North Carolina • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 2, 2026, 3:34 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic

NCT04388605
View directory record Official record
Conditions
Corona Virus Infection, COVID, Pregnancy Related, Early Pregnancy
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
7,965 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 2, 2026, 3:34 AM EDT
Not listed Not applicable Interventional

Quantifying Viral Load in Respiratory Particles That Are Generated by Children and Adults With COVID-19 Infection

NCT05195229
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 Aerosol Collection
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

NCT01928472
View directory record Official record
Conditions
H7N9 Influenza
Interventions
H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant, H7N9c high dose without adjuvant
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 64 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
6
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 2, 2026, 3:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Collection of Anti-SARS-CoV-2 Immune Plasma

NCT04344977
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Torrance, California • Miami, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

NCT00782431
View directory record Official record
Conditions
Influenza
Interventions
Vero cell derived, trivalent, seasonal influenza vaccine, Licensed egg-derived, trivalent seasonal influenza vaccine
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
50 Years and older
Enrollment
3,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
30
States / cities
Mobile, Alabama • Tucson, Arizona • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 2, 2026, 3:34 AM EDT
Completed Phase 2 Interventional

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

NCT00307177
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 2, 2026, 3:34 AM EDT